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BACKGROUND
Severe coronavirus disease 2019 (Covid-19) is associated with dysregulated inflam-
mation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, 
plus remdesivir are not known.
METHODS
We conducted a double-blind, randomized, placebo-controlled trial evaluating 
baricitinib plus remdesivir in hospitalized adults with Covid-19. All the patients 
received remdesivir (≤10 days) and either baricitinib (≤14 days) or placebo (control). 
The primary outcome was the time to recovery. The key secondary outcome was 
clinical status at day 15.
RESULTS
A total of 1033 patients underwent randomization (with 515 assigned to combina-
tion treatment and 518 to control). Patients receiving baricitinib had a median 
time to recovery of 7 days (95% confidence interval [CI], 6 to 8), as compared with 
8 days (95% CI, 7 to 9) with control (rate ratio for recovery, 1.16; 95% CI, 1.01 to 
1.32; P = 0.03), and a 30% higher odds of improvement in clinical status at day 15 
(odds ratio, 1.3; 95% CI, 1.0 to 1.6). Patients receiving high-flow oxygen or non-
invasive ventilation at enrollment had a time to recovery of 10 days with combina-
tion treatment and 18 days with control (rate ratio for recovery, 1.51; 95% CI, 1.10 
to 2.08). The 28-day mortality was 5.1% in the combination group and 7.8% in the 
control group (hazard ratio for death, 0.65; 95% CI, 0.39 to 1.09). Serious adverse 
events were less frequent in the combination group than in the control group (16.0% 
vs. 21.0%; difference, −5.0 percentage points; 95% CI, −9.8 to −0.3; P = 0.03), as were 
new infections (5.9% vs. 11.2%; difference, −5.3 percentage points; 95% CI, −8.7 to 
−1.9; P = 0.003).
CONCLUSIONS
Baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery 
time and accelerating improvement in clinical status among patients with Covid-19, 
notably among those receiving high-flow oxygen or noninvasive ventilation. The 
combination was associated with fewer serious adverse events. (Funded by the Na-
tional Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, 
NCT04401579.)
A BS TR AC T
Baricitinib plus Remdesivir for Hospitalized 
Adults with Covid-19
A.C. Kalil, T.F. Patterson, A.K. Mehta, K.M. Tomashek, C.R. Wolfe, V. Ghazaryan, 
V.C. Marconi, G.M. Ruiz-Palacios, L. Hsieh, S. Kline, V. Tapson, N.M. Iovine, 
M.K. Jain, D.A. Sweeney, H.M. El Sahly, A.R. Branche, J. Regalado Pineda, 
D.C. Lye, U. Sandkovsky, A.F. Luetkemeyer, S.H. Cohen, R.W. Finberg, 
P.E.H. Jackson, B. Taiwo, C.I. Paules, H. Arguinchona, P. Goepfert, N. Ahuja, 
M. Frank, M. Oh, E.S. Kim, S.Y. Tan, R.A. Mularski, H. Nielsen, P.O. Ponce, 
B.S. Taylor, L.A. Larson, N.G. Rouphael, Y. Saklawi, V.D. Cantos, E.R. Ko, 
J.J. Engemann, A.N. Amin, M. Watanabe, J. Billings, M.-C. Elie, R.T. Davey, 
T.H. Burgess, J. Ferreira, M. Green, M. Makowski, A. Cardoso, S. de Bono, T. Bonnett, 
M. Proschan, G.A. Deye, W. Dempsey, S.U. Nayak, L.E. Dodd, and J.H. Beigel 
Original Article
The New England Journal of Medicine 
Downloaded from nejm.org at UMass Medical School on December 23, 2020. For personal use only. No other uses without permission. 
 Copyright © 2020 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 2
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
In May 2020, the first stage of the Adaptive Covid-19 Treatment Trial (ACTT-1), a randomized, double-blind, placebo-con-
trolled trial, showed that remdesivir is an effec-
tive treatment for hospitalized adult patients with 
coronavirus disease 2019 (Covid-19) pneumonia.1 
Despite the benefits of remdesivir, substantial 
morbidity and mortality due to Covid-19 remain. 
Emerging data suggest that disease severity may 
be due in part to a dysregulated inflammatory 
response.2 It is postulated that mitigating the im-
mune response and preventing a hyperinflamma-
tory state may further improve clinical outcomes. 
Baricitinib, an orally administered, selective in-
hibitor of Janus kinase (JAK) 1 and 2, was pre-
dicted with the use of artificial intelligence algo-
rithms to be a potential therapeutic against 
severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2).3,4 Baricitinib inhibits the intracel-
lular signaling pathway of cytokines known to be 
elevated in severe Covid-19, including interleukin-2, 
interleukin-6, interleukin-10, interferon-γ, and 
granulocyte–macrophage colony-stimulating fac-
tor; acts against SARS-CoV-2 through the im-
pairment of AP2-associated protein kinase 1 and 
the prevention of SARS-CoV-2 cellular entry and 
infectivity; and improves lymphocyte counts in 
patients with Covid-19.3,5-8 In three case series of 
patients with Covid-19, baricitinib treatment was 
associated with both an improvement in oxygen-
ation and a reduction in select inflammatory 
markers.9-11 Randomized, controlled trials are 
needed to further understand the role of immu-
nomodulation in patients with Covid-19.12 After 
the successful completion of ACTT-1, we de-
signed the next iteration of ACTT (ACTT-2) to 
evaluate whether the combination of baricitinib 
plus remdesivir was superior to remdesivir alone.
Me thods
Design
The ACTT-2 protocol was designed and written 
by a working group of the ACTT investigators and 
the sponsor (the National Institute of Allergy and 
Infectious Diseases), with input from the manu-
facturer of baricitinib, Eli Lilly. Investigators and 
staff at participating sites gathered the data, 
which were then analyzed by statisticians at the 
statistical and data center (Emmes) and the 
sponsor. The authors wrote the manuscript, and, 
on behalf of the ACTT-2 Study Group, vouch for 
the accuracy and completeness of the data and 
for the fidelity of the trial to the protocol.
Enrollment into this double-blind, placebo-
controlled trial began on May 8, 2020, and ended 
on July 1, 2020. There were 67 trial sites in 8 coun-
tries: the United States (55 sites), Singapore (4), 
South Korea (2), Mexico (2), Japan (1), Spain (1), 
the United Kingdom (1), and Denmark (1). Eli-
gible patients were randomly assigned in a 1:1 
ratio to receive either remdesivir and baricitinib 
or remdesivir and placebo. Randomization was 
stratified according to trial site and disease se-
verity at enrollment (see the Supplementary Ap-
pendix, available with the full text of this article at 
NEJM.org). Patients received remdesivir intrave-
nously as a 200-mg loading dose on day 1, fol-
lowed by a 100-mg maintenance dose adminis-
tered daily on days 2 through 10 or until hospital 
discharge or death. Baricitinib was administered 
as a 4-mg daily dose (either orally [two 2-mg tab-
lets] or through a nasogastric tube) for 14 days or 
until hospital discharge. Patients with an estimat-
ed glomerular filtration rate of less than 60 ml per 
minute received baricitinib at a dose of 2 mg 
once daily. A matching oral placebo was admin-
istered according to the same schedule as the 
active drug. All the patients received standard 
supportive care at the trial site hospital. Venous 
thromboembolism prophylaxis was recommend-
ed for all the patients without a major contrain-
dication. If a hospital had a written policy for 
Covid-19 treatments, patients could receive those 
treatments. In the absence of a written policy, 
other experimental treatment and off-label use 
of marketed medications intended as specific 
treatment for Covid-19 were prohibited. This in-
cluded glucocorticoids, which were permitted only 
for standard indications such as adrenal insuffi-
ciency, asthma exacerbation, laryngeal edema, 
septic shock, and acute respiratory distress 
syndrome.
The trial protocol was approved by the insti-
tutional review board at each site (or a centralized 
institutional review board as applicable) and was 
overseen by an independent data and safety moni-
toring board. Written informed consent was ob-
tained from each patient or from the patient’s 
legally authorized representative if the patient 
was unable to provide consent. Full details of 
the trial design, conduct, oversight, and analyses 
are provided in the protocol and statistical analy-
sis plan (available at NEJM.org).
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Procedures
All patients were evaluated daily during their 
hospitalization, from day 1 through day 29. (See 
the full description of procedures in the Supple-
mentary Appendix.) The trial team was unaware 
of the trial-group assignments until after all data 
queries were resolved and the database was locked. 
The first draft of the manuscript was written by the 
first author, and then all the authors contributed 
to the subsequent versions. No one who is not an 
author contributed to the writing of the manu-
script.
Outcomes and Statistical Analysis
The primary outcome measure was the time to 
recovery, with the day of recovery defined as the 
first day, during the 28 days after enrollment, on 
which a patient attained category 1, 2, or 3 on 
the eight-category ordinal scale. The competing 
event of death was handled in a manner similar 
to the Fine–Gray competing-risk approach.13 The 
categories are the same as those used in ACTT-11 
and are listed in Table S1 in the Supplementary 
Appendix. The primary analysis was a stratified 
log-rank test of the time to recovery with remde-
sivir plus baricitinib as compared with remdesi-
vir plus placebo, stratified according to baseline 
disease severity (i.e., score on the ordinal scale of 
4 or 5 vs. 6 or 7 at enrollment).
The key secondary outcome measure was clini-
cal status at day 15, based on the eight-category 
ordinal scale. Other secondary outcome measures 
included the time to improvement by one or two 
categories from the ordinal score at baseline; 
clinical status, as assessed on the ordinal scale 
at days 3, 5, 8, 11, 15, 22, and 29; mean change 
in the ordinal score from day 1 to days 3, 5, 8, 
11, 15, 22, and 29; time to discharge or to a 
National Early Warning Score of 2 or less (on a 
scale from 0 to 20, with higher scores indicat-
ing greater clinical risk) that was maintained 
for 24 hours, whichever occurred first; change in 
the National Early Warning Score from day 1 to 
days 3, 5, 8, 11, 15, 22, and 29; number of days 
of receipt of supplemental oxygen, noninvasive 
ventilation or high-flow oxygen, and invasive ven-
tilation or extracorporeal membrane oxygenation 
(ECMO) up to day 29 (if these were being used 
at baseline); the incidence and duration of new 
use of oxygen, new use of noninvasive ventilation 
or high-flow oxygen, and new use of invasive ven-
tilation or ECMO; duration of hospitalization up 
to day 29 (patients who remained hospitalized at 
day 29 had a value of 28 days); and mortality at 
14 and 28 days after enrollment. Secondary safety 
outcomes included grade 3 and 4 adverse events 
and serious adverse events that occurred through 
day 29, discontinuation or temporary suspension 
of trial-product administration for any reason, and 
changes in assessed laboratory values over time. 
There was a single primary hypothesis test. For 
secondary outcomes, no adjustments for multi-
plicity were made.
Prespecified subgroups were defined accord-
ing to sex, disease severity (as defined for stratifi-
cation and by an ordinal score of 4, 5, 6, and 7 at 
enrollment), age (18 to 39 years, 40 to 64 years, 
or ≥65 years), race, ethnic group, duration of symp-
toms before randomization (measured as ≤10 days 
or >10 days, in quartiles, and as the median), site 
location, and presence of coexisting conditions.
R esult s
Patients
Of 1067 patients assessed for eligibility, 1033 
underwent randomization; 515 were assigned to 
the combination group, and 518 to the control 
group (Fig. 1). The intention-to-treat population 
included 706 patients with moderate disease 
(ordinal score of 4 or 5 [not receiving ventilation]) 
and 327 with severe disease (ordinal score of 6 or 
7 [receiving noninvasive or invasive ventilation]). 
Of those assigned to the combination group, 507 
(98.4%) received treatment as assigned. Of those 
assigned to the control group, 509 (98.3%) received 
treatment as assigned. A total of 498 patients in 
the combination group and 495 in the control 
group completed the trial through day 29, recov-
ered, or died. The mean age of the patients was 
55.4 years, and 63.1% were male (Table 1). Over-
all, 48.0% of the patients were White, 15.1% were 
Black, 9.8% were Asian, and 1.0% were American 
Indian or Alaska Native; 51.4% were Hispanic or 
Latino (Table 1). The characteristics of the U.S. 
patients are shown in Table S4.
Primary Outcome
Patients who received combination treatment 
with baricitinib plus remdesivir recovered a me-
dian of 1 day faster than patients who received 
remdesivir and placebo (median, 7 days vs. 8 days; 
rate ratio for recovery, 1.16; 95% confidence in-
terval [CI], 1.01 to 1.32; P = 0.03 by log-rank test 
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Figure 1. Enrollment and Randomization.
RDV denotes remdesivir.
1033 Underwent randomization
1067 Patients were assessed for eligibility
34 Were excluded
29 Were ineligible owing to meeting exclusion
criteria or not meeting inclusion criteria
5 Were eligible but were not enrolled
515 Were assigned to receive baricitinib+RDV
508 Received infusion
507 Received tablet
7 Were enrolled but did not receive any treatment
518 Were assigned to receive placebo+RDV
509 Received infusion
509 Received tablet
9 Were enrolled but did not receive any treatment
515 Were included in the intention-to-treat population
507 Were included in the as-treated population
    8 Were excluded from as-treated population owing
      to not receiving at least 1 tablet
66 Discontinued intervention (deaths and discharges
excluded)
31 Were receiving tablets
22 Had severe adverse event or adverse event other
than death
4 Had protocol deviation
3 Withdrew
1 Was withdrawn by investigator
1 Became ineligible after enrollment
5 Were receiving infusions
1 Had severe adverse event or adverse event other
than death
1 Had a technical problem
1 Was withdrawn by investigator
1 Became ineligible after enrollment
1 Had other reason
33 Were receiving both trial products
21 Had severe adverse event or adverse event other
than death
1 Had protocol deviation
8 Withdrew
3 Were withdrawn by investigator
84 Discontinued participation in trial early
23 Died
40 Were lost to follow-up
8 Withdrew
1 Were withdrawn by investigator
1 Became ineligible after enrollment
7 Were enrolled but did not receive treatment
2 Had severe adverse event or adverse event other
than death
2 Had other reason
94 Discontinued intervention (deaths and discharges
excluded)
39 Were receiving tablets
33 Had severe adverse event or adverse event other
than death
1 Had protocol deviation
1 Withdrew
3 Were withdrawn by investigator
1 Had a technical problem
13 Were receiving infusions
10 Had severe adverse event or adverse event other
than death
1 Had a technical problem
1 Was withdrawn by investigator
1 Had protocol deviation
50 Were receiving both trial products
25 Had severe adverse event or adverse event other
than death
1 Had protocol deviation
13 Withdrew
6 Were withdrawn by investigator
3 Were transferred to another hospital
1 Became ineligible after enrollment
1 Had other reason
110 Discontinued participation in trial early
36 Died
41 Were lost to follow-up
16 Withdrew
2 Were withdrawn by investigator
1 Became ineligible after enrollment
9 Were enrolled but did not receive treatment
1 Had severe adverse event or adverse event other
than death
1 Was transferred to another hospital
3 Had other reason
518 Were included in the intention-to-treat population
509 Were included in the as-treated population
    9 Were excluded from as-treated population owing
      to not receiving at least 1 tablet
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Mean — yr 55.4±15.7 55.0±15.4 55.8±16.0
Distribution — no. (%)
<40 yr 173 (16.7) 87 (16.9) 86 (16.6)
40–64 yr 555 (53.7) 281 (54.6) 274 (52.9)
≥65 yr 305 (29.5) 147 (28.5) 158 (30.5)
Sex — no. (%)
Female 381 (36.9) 196 (38.1) 185 (35.7)
Male 652 (63.1) 319 (61.9) 333 (64.3)
Race — no. (%)†
Asian 101 (9.8) 49 (9.5) 52 (10.0)
Black 156 (15.1) 77 (15.0) 79 (15.3)
White 496 (48.0) 251 (48.7) 245 (47.3)
Other or unknown 280 (27.1) 138 (26.8) 142 (27.4)
Ethnic group — no. (%)†
Hispanic or Latino 531 (51.4) 263 (51.1) 268 (51.7)
Not Hispanic or Latino 486 (47.0) 246 (47.8) 240 (46.3)
Not reported or unknown 16 (1.5) 6 (1.2) 10 (1.9)
Body-mass index‡ 32.2±8.3 32.2±8.2 32.3±8.4
Median time (IQR) from symptom onset to ran-
domization — days
8 (5–10) 8 (5–10) 8 (5–11)
Disease severity — no. (%)
Moderate 706 (68.3) 358 (69.5) 348 (67.2)
Severe 327 (31.7) 157 (30.5) 170 (32.8)
Coexisting conditions — no./total no. (%)
None 155/994 (15.6) 64/496 (12.9) 91/498 (18.3)
One 270/994 (27.2) 148/496 (29.8) 122/498 (24.5)
Two or more 569/994 (57.2) 284/496 (57.3) 285/498 (57.2)
Score on ordinal scale — no. (%)
4. Hospitalized, not requiring supplemental 
oxygen, requiring ongoing medical care 
(Covid-19–related or otherwise)
142 (13.7) 70 (13.6) 72 (13.9)
5. Hospitalized, requiring supplemental oxygen 564 (54.6) 288 (55.9) 276 (53.3)
6. Hospitalized, receiving noninvasive ventila-
tion or high-flow oxygen devices
216 (20.9) 103 (20.0) 113 (21.8)
7. Hospitalized, receiving invasive mechanical 
ventilation or ECMO
111 (10.7) 54 (10.5) 57 (11.0)
Geographic region — no. (%)
Asia 67 (6.5) 33 (6.4) 34 (6.6)
Europe 13 (1.3) 6 (1.2) 7 (1.4)
North America 953 (92.3) 476 (92.4) 477 (92.1)
*  Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. Covid-19 denotes coronavirus 
disease 2019, ECMO extracorporeal membrane oxygenation, IQR interquartile range, and RDV remdesivir.
†  Race and ethnic group were reported by the patients. With respect to “other” race, the categories that were used when 
data on race were reported included American Indian or Alaska Native and Native Hawaiian or other Pacific Islander.
‡  The body-mass index is the weight in kilograms divided by the square of the height in meters.
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Figure 2. Kaplan–Meier Estimates of Cumulative Recoveries.
Cumulative recovery estimates are shown in the overall population (Panel A), in patients with a baseline score of 4 on the ordinal scale 
(not requiring oxygen; Panel B), in those with a baseline score of 5 (requiring oxygen; Panel C), in those with a baseline score of 6 (re-
ceiving high-flow oxygen or noninvasive mechanical ventilation; Panel D), and in those with a baseline score of 7 (receiving mechanical 
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stratified according to actual baseline severity) 
(Fig. 2 and Table 2). When analyzed according to 
the severity entered at the time of randomization 
(moderate vs. severe), the hazard ratio was 1.15 
(95% CI, 1.00 to 1.31; P = 0.047) (Table S6). The 
median time to recovery among patients receiv-
ing noninvasive ventilation or high-flow oxygen 
(baseline ordinal score of 6) was 10 days in the 
combination group and 18 days in the control 
group (rate ratio for recovery, 1.51; 95% CI, 1.10 
to 2.08). Among patients with a baseline score of 
4 (no oxygen) and 5 (supplemental oxygen), the 
rate ratio for recovery was 0.88 (95% CI, 0.63 to 
1.23) and 1.17 (95% CI, 0.98 to 1.39), respectively. 
For those receiving mechanical ventilation or 
ECMO at enrollment (baseline ordinal score of 7), 
the rate ratio for recovery was 1.08 (95% CI, 0.59 
to 1.97) (Table 2 and Fig. 3). The rate ratio for 
recovery among the 223 patients who received 
glucocorticoids for clinical indications during the 
trial was 1.06 (95% CI, 0.75 to 1.48). A sensitivity 
analysis with a random effect for hospital site 
yielded similar results (conditional random-effects 
estimate of rate ratio for recovery, 1.16; 95% CI, 
1.01 to 1.33; restricted maximum likelihood–based 
random-effects estimate of variance, 0.0305) (Ta-
ble S13).
Key Secondary Outcome
The odds of improvement in clinical status at 
day 15 as assessed with the ordinal scale were 
greater in the combination group than in the con-
trol group (odds ratio for improvement, 1.3; 95% 
CI, 1.0 to 1.6). Patients with a baseline ordinal 
score of 6 who received combination treatment 
were most likely to have clinical improvement at 
day 15 (odds ratio, 2.2; 95% CI, 1.4 to 3.6) (Ta-
ble 2 and Fig. S1).
Mortality
The Kaplan–Meier estimates of mortality at day 28 
after randomization were 5.1% (95% CI, 3.5 to 7.6) 
in the combination group and 7.8% (95% CI, 5.7 
to 10.6) in the control group (hazard ratio for 
death, 0.65; 95% CI, 0.39 to 1.09). The greatest 
numerical differences in mortality between pa-
tients in the combination group and those in the 
control group were observed among those with a 
baseline ordinal score of 5 (1.9% vs. 4.7%; hazard 
ratio, 0.40; 95% CI, 0.14 to 1.14) or 6 (7.5% vs. 
12.9%; hazard ratio, 0.55; 95% CI, 0.22 to 1.38). 
The Kaplan–Meier estimates of mortality at 14 days 
after randomization were 1.6% in the combination 
group and 3.0% in the control group (hazard ratio, 
0.54; 95% CI, 0.23 to 1.28) (Table 2 and Fig. S2).
Additional Secondary Outcomes
The median time to an improvement by one cate-
gory on the ordinal scale was 6 days in the combi-
nation group and 8 days in the control group (rate 
ratio, 1.21; 95% CI, 1.06 to 1.39), and the median 
time to discharge or a National Early Warning 
Score of 2 or less for 24 hours was 6 days and 
7 days in the respective groups (rate ratio, 1.24; 
95% CI, 1.07 to 1.44) (Table 3). The incidence of 
new use of oxygen was lower in the combination 
group than in the control group (22.9% vs. 40.3%; 
difference, −17.4 percentage points; 95% CI, −31.6 
to −2.1), as was the incidence of new use of me-
chanical ventilation or ECMO (10.0% vs. 15.2%; 
difference, −5.2 percentage points; 95% CI, −9.5 
to −0.9). The median number of days of receipt 
of mechanical ventilation or ECMO among the 
128 patients in whom these interventions were 
started after enrollment or who died with no ob-
served new use was 16 days in the combination 
group and 27 days in the control group (differ-
ence, −11.0; 95% CI, −18.3 to −3.7). The incidence 
of progression to death or noninvasive or inva-
sive ventilation was lower in the combination 
group than in the control group (22.5% vs. 28.4%; 
rate ratio, 0.77; 95% CI, 0.60 to 0.98), as was the 
incidence of progression to death or invasive 
ventilation (12.2% vs. 17.2%; rate ratio, 0.69; 
95% CI, 0.50 to 0.95).
Safety Outcomes
Grade 3 or 4 adverse events occurred in 207 pa-
tients (40.7%) in the combination group and 238 
(46.8%) in the control group (Table S11). A total 
of 25 grade 3 or 4 adverse events were judged by 
the principal investigators to be related to com-
bination treatment and 28 to control (Table S10). 
The most common grade 3 or 4 adverse events 
occurring in at least 5% of all patients were hyper-
glycemia, anemia, decreased lymphocyte count, 
and acute kidney injury (Table S10). The inci-
dence of these adverse events was similar in the 
two treatment groups. The percentage of patients 
who were reported to have a serious or nonseri-
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ous adverse event of venous thromboembolism 
was similar in the combination group and the 
control group (21 patients [4.1%] and 16 patients 
[3.1%], respectively; difference, 1.0 percentage 
points; 95% CI, −1.3 to 3.3).
Serious adverse events occurred in 81 patients 
(16.0%) in the combination group, and six of these 
events were thought to be related to the trial prod-
uct (Table S7). Serious adverse events occurred in 
107 patients (21.0%) in the control group, and 
five of these events were thought to be related to 
the trial product. The between-group difference 
was −5.0 percentage points (95% CI, −9.8 to −0.3; 
P = 0.03). The incidences of all serious adverse 
events, all adverse events, serious adverse events 
with fatal outcome, and adverse events leading 
to discontinuation of the trial product were each 
lower in the combination group than in the con-
trol group. Overall, the incidence of serious or 
nonserious adverse events of new infection was 
lower in the combination group (30 patients 
[5.9%]) than in the control group (57 patients 
[11.2%]) (difference, −5.3 percentage points; 
95% CI, −8.7 to −1.9; P = 0.003). Patients who re-
ceived glucocorticoids after randomization had a 
higher incidence of serious or nonserious new in-
fection than those who did not (56 of 223 patients 
[25.1%] vs. 44 of 793 patients [5.5%]).
Figure 3. Time to Recovery According to Subgroup.
The widths of the confidence intervals have not been adjusted for multiplicity and therefore cannot be used to infer 
treatment effects. Race and ethnic group were reported by the patients. With respect to “other” race, the categories 
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Table 3. Additional Secondary Outcomes.
Outcome Baricitinib+RDV Placebo+RDV Rate Ratio (95% CI)
Median time to event (95% CI) — days
Improvement by one category on ordinal scale 6.0 (5.0 to 7.0) 8.0 (7.0 to 9.0) 1.21 (1.06 to 1.39)
Improvement by two categories on ordinal scale 12.0 (12.0 to 13.0) 13.0 (NE) 1.20 (1.05 to 1.38)
Discharge or National Early Warning Score ≤2 for 24 hr* 6.0 (6.0 to 7.0) 7.0 (6.0 to 9.0) 1.24 (1.07 to 1.44)
Death or progression to noninvasive or invasive mechanical ventilation NE NE 0.77 (0.60 to 0.98)
Death or progression to invasive mechanical ventilation NE NE 0.69 (0.50 to 0.95)
New use of oxygen NE NE (3.0 to NE) 0.53 (0.29 to 0.98)
New use of invasive mechanical ventilation or ECMO NE NE 0.64 (0.44 to 0.93)
Use of noninvasive ventilation or high-flow oxygen NE NE 0.82 (0.60 to 1.13)
Difference (95% CI)
Hospitalization
Median duration of initial hospitalization (IQR) — days
With imputation of data for those who died† 8 (5 to 15) 8 (5 to 20) 0.0 (−1.1 to 1.1)
Among those who did not die 8 (5 to 13) 8 (5 to 15) 0.0 (−1.0 to 1.0)
Patients rehospitalized — % (95% CI) 3 (2 to 5) 2 (1 to 4) 1.0 (−1.1 to 3.1)‡
Oxygen
Median days receiving oxygen if receiving oxygen at baseline (IQR)
With imputation of data for those who died† 10 (4 to 27) 12 (4 to 28) −2.0 (−5.2 to 1.2)
Among those who did not die 9 (4 to 23) 10 (4 to 28) −1.0 (−3.5 to 1.5)
New use of oxygen during trial
No. of patients/total no. 16/70 29/72
Percent of patients (95% CI) 23 (15 to 34) 40 (30 to 52) −17.4 (−31.6 to −2.1)‡
Median days receiving oxygen (IQR) 3 (2 to 4) 3 (2 to 6) 0.0 (−2.2 to 2.2)
Noninvasive ventilation or high-flow oxygen
Median days of noninvasive ventilation or high-flow oxygen use during 
trial if receiving these interventions at baseline (IQR)
With imputation of data for those who died† 4 (3 to 9) 5 (2 to 12) −1.0 (−2.9 to 0.9)
Among those who did not die 4 (3 to 6) 4 (2 to 9) 0.0 (−1.7 to 1.7)
New use of noninvasive ventilation or high-flow oxygen during trial
No. of patients/total no. 70/358 82/348
Percent of patients (95% CI) 20 (16 to 24) 24 (19 to 28) −4.0 (−10.1 to 2.1)‡
Median days of use during trial (IQR) 6 (3 to 13) 4 (2 to 11) 2.0 (−0.4 to 4.4)
Mechanical ventilation or ECMO
Median days of mechanical ventilation or ECMO during trial if receiv-
ing these interventions at baseline (IQR)
With imputation of data for those who died† 20 (9 to 28) 25 (11 to 28) −5.0 (−12.9 to 2.9)
Among those who did not die 13 (7 to 24) 16 (6 to 28) −2.0 (−11.4 to 7.4)
New use of mechanical ventilation or ECMO during trial
No. of patients/total no. 46/461 70/461
Percent of patients (95% CI) 10 (8 to 13) 15 (12 to 19) −5.2 (−9.5 to −0.9)‡
Median days of use during trial§ 16 (7 to 28) 27 (12 to 28) −11.0 (−18.3 to −3.7)
*  The National Early Warning Score includes six physiological measures; total scores range from 0 to 20, with higher scores indicating greater 
clinical risk. Only patients with a score of more than 2 at baseline were included in this analysis.
†  The value for patients who died was imputed as 28 days.
‡  Differences between percentages are given in percentage points.
§  This analysis includes imputation of data for patients who died with no observed new use. A total of 12 patients died without progression to 
ECMO. All the patients who died had other oxygen use.
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Discussion
The results of this randomized, double-blind, pla-
cebo-controlled trial show that combination treat-
ment with the antiinflammatory drug baricitinib 
and the antiviral drug remdesivir was safe and 
superior to remdesivir alone for the treatment of 
hospitalized patients with Covid-19 pneumonia. 
The beneficial effects of the combination treat-
ment were seen both in the primary outcome, 
with a 1-day shorter time to recovery, and in the 
key secondary outcome, with a greater improve-
ment in clinical status as assessed on the ordinal 
scale. Although ACTT-2 was not powered to de-
tect a difference in mortality between the two 
groups, both the survival rate and the time-to-
death analyses favored combination treatment. 
These clinical benefits were observed across 
different age groups, sexes, ethnic groups, and 
races and were independent of symptom dura-
tion or disease severity at enrollment. The large 
proportion of Hispanic or Latino patients who 
were enrolled in the trial reflects the dispropor-
tionate effect of the pandemic on racial and 
ethnic minorities with respect to high incidenc-
es of hospitalization.14
The observed benefit of combination treatment 
was most evident in patients with a baseline ordi-
nal score of 5 (supplemental oxygen) or 6 (high-
flow oxygen or noninvasive ventilation), among 
whom the median time to recovery was, respec-
tively, 1 and 8 days sooner with combination 
treatment than with placebo. Patients with a 
baseline ordinal score of 6 who received combi-
nation treatment were twice as likely as those in 
the control group to have improved clinical sta-
tus at day 15 (odds ratio, 2.2; 95% CI, 1.4 to 3.6). 
The faster recovery in patients who received bar-
icitinib plus remdesivir suggests that the combi-
nation treatment may have an effect in lowering 
the hospital-associated risk of nosocomial infec-
tions, thrombosis, and errors in hospital drug 
administration. Moreover, faster recovery also 
decreases the burden on the health care system, 
potentially increasing capacity, which is of critical 
importance during a surge of cases.
In addition, the combination treatment showed 
clinical benefits directly relevant to patient care, 
such as a difference of −17.4 percentage points 
in new use of oxygen (22.9% vs. 40.3%) and a 
difference of −5.2 percentage points in new use 
of mechanical ventilation or ECMO (10.0% vs. 
15.2%). In fact, the odds of progression to death 
or invasive ventilation were 31% lower in the 
combination group than in the control group 
(hazard ratio, 0.69; 95% CI, 0.50 to 0.95), and 
patients in the combination group had 11 fewer 
days receiving new mechanical ventilation than 
those in the control group.
Despite concerns about immunosuppression, 
secondary infections, and thrombosis with use 
of JAK inhibitors, the addition of baricitinib was 
not associated with a significantly higher incidence 
of adverse events or thromboembolic events. In 
fact, patients receiving baricitinib plus remdesi-
vir had a significantly lower incidence of adverse 
events, adverse events leading to discontinuation 
of the trial drug, serious adverse events, serious 
adverse events with a fatal outcome, and infec-
tion-related adverse events than patients who 
received remdesivir alone. The consistently lower 
incidence of adverse events with baricitinib may 
be related to its action in reducing inflammatory-
mediated lung injury and improving lymphocyte 
counts, its antiviral properties, or its associated 
shorter recovery time and faster clinical improve-
ment, all of which could have reduced the risk of 
nosocomial infection. Another ongoing trial 
may provide more information regarding the ef-
fects of baricitinib (ClinicalTrials.gov number, 
NCT04421027). In summary, our results and the 
characteristics of baricitinib, including the fact 
that it is an oral drug with few drug–drug inter-
actions and a good safety profile, lend itself to 
use in low-to-middle-income countries.
The Randomized Evaluation of Covid-19 
Therapy (RECOVERY) trial evaluated dexametha-
sone in patients with Covid-1915 and showed a 
significant benefit in survival, most pronounced 
in patients receiving mechanical ventilation, and 
a 1-day shorter hospital stay. Baricitinib and 
dexamethasone have important biologic differ-
ences, and ACTT-2 and the RECOVERY trial have 
design differences. Dexamethasone has a long 
half-life, acts on glucocorticoid receptors, and 
reduces inflammation through a broad-pathway 
approach that has been associated with immuno-
suppression, hospital-acquired infections, gastro-
intestinal bleeding, hyperglycemia, and neuro-
muscular weakness, even with short courses.16 
Baricitinib has a short half-life, acts on targeted 
critical pathways to reduce inflammation while 
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minimizing biologic redundancy with less im-
munosuppression, and may have antiviral activ-
ity.3 The two trials had different designs and 
cannot be compared directly. The high mortality 
in the control group of the RECOVERY trial and 
the low mortality in the control group of ACTT-2 
suggest that these trials might not be generaliz-
able to the same patient population. Only a ran-
domized, double-blind, placebo-controlled, head-
to-head comparison of baricitinib plus remdesivir 
with dexamethasone plus remdesivir will allow 
the efficacy and safety differences between these 
two approaches to be fully understood.
Baricitinib plus remdesivir was superior to 
remdesivir alone in reducing recovery time and 
accelerating improvement in clinical status, no-
tably among patients receiving high-flow oxygen 
or noninvasive mechanical ventilation. The com-
bination was associated with fewer serious ad-
verse events.
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